Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters

Trial Profile

An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Midazolam (Primary)
  • Indications Generalised epilepsy; Partial epilepsies; Seizures
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARTEMIS 2
  • Sponsors Proximagen; Upsher-Smith
  • Most Recent Events

    • 29 Jul 2019 Results assessing safety and efficacy of midazolam nasal spray in patients with seizures, published in the Epilepsia.
    • 04 Dec 2018 Results of long-term efficacy presented at the 72nd Annual Meeting of the American Epilepsy Society.
    • 04 Dec 2018 Results of long-term safety presented at the 72nd Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top